- Home
- BLKB vs DYN Comparison
BLKB vs DYN Comparison
Compare BLKB & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLKB
- DYN
- Stock Information
- Founded
- BLKB 1981
- DYN 1984
- Country
- BLKB United States
- DYN United States
- Employees
- BLKB N/A
- DYN N/A
- Industry
- BLKB Computer Software: Prepackaged Software
- DYN Medicinal Chemicals and Botanical Products
- Sector
- BLKB Technology
- DYN Health Care
- Exchange
- BLKB Nasdaq
- DYN Nasdaq
- Market Cap
- BLKB 3.1B
- DYN 848.8M
- IPO Year
- BLKB 2004
- DYN 2020
- Fundamental
- Price
- BLKB $64.15
- DYN $11.30
- Analyst Decision
- BLKB Hold
- DYN Strong Buy
- Analyst Count
- BLKB 3
- DYN 12
- Target Price
- BLKB $78.67
- DYN $47.73
- AVG Volume (30 Days)
- BLKB 322.9K
- DYN 2.7M
- Earning Date
- BLKB 04-30-2025
- DYN 05-08-2025
- Dividend Yield
- BLKB N/A
- DYN N/A
- EPS Growth
- BLKB N/A
- DYN N/A
- EPS
- BLKB N/A
- DYN N/A
- Revenue
- BLKB $1,146,906,000.00
- DYN N/A
- Revenue This Year
- BLKB N/A
- DYN N/A
- Revenue Next Year
- BLKB $4.05
- DYN N/A
- P/E Ratio
- BLKB N/A
- DYN N/A
- Revenue Growth
- BLKB 2.13
- DYN N/A
- 52 Week Low
- BLKB $58.05
- DYN $6.36
- 52 Week High
- BLKB $88.95
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- BLKB 56.25
- DYN 55.04
- Support Level
- BLKB $60.25
- DYN $9.17
- Resistance Level
- BLKB $63.50
- DYN $12.47
- Average True Range (ATR)
- BLKB 1.67
- DYN 1.02
- MACD
- BLKB 0.31
- DYN 0.12
- Stochastic Oscillator
- BLKB 74.31
- DYN 73.65
About BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.